Newsroom
October 8, 2025
SQ Innovation Announces FDA Approval of Lasix® ONYU for Treatment of Edema in Heart Failure
SQ Innovation, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved its drug-device combination Lasix® ONYU (furosemide injection) for the treatment of edema (due to fluid overload) in adult patients with chronic heart failure
October 8, 2025
SQ Innovation AG Announces the Appointment of Two New Board Members and Successful Closing of Series B Financing to Support the U.S. Launch of Lasix® ONYU
SQ Innovation AG, a life-science company pioneering innovative solutions for the treatment of worsening heart failure, today announced the appointment of two distinguished executives to its Board of Directors: Mr. Marco van der Poel and Mr. Erik Massmann.
July 8, 2019
Ligand and SQ Innovation Enter into Exclusive Worldwide Captisol® License and Supply Agreements for High-Concentration Furosemide Formulation
SQ Innovation will use Ligand’s Captisol technology to achieve a smaller delivery volume for more cost-effective diuretic treatment in heart failure.